All clinical trials are reviewed by an Institutional Review Board (IRB) to protect the rights and safety of people who join. But some trials stand out because they’re doing more for patients. Our review committee of patients and researchers helped identify some trials that are going above and beyond. They are our featured trials.
- CAR T cells (CD33CART) to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory) in children and young adultsTo find out:
- The highest dose of CD33CART that is safe to give
- If CD33CART is safe and works well to treat AML that has relapsed or is refractory in children and young adults
- Donor Search Prognosis (DSP) score to help choose the best donor before allogeneic (cells from a donor) blood or marrow transplant (BMT)To find out if donor selection based on an individual’s DSP score gets patients to allogeneic BMT more quickly and with better outcomes.
- Gene therapy, using T cells (HA-1 TCR) from a donor, to treat acute leukemia that has come back (relapsed) after getting an allogeneic (cells from a donor) blood or marrow transplant (BMT)To find out:
- The highest dose of HA-1 TCR T cells that is safe to give
- If HA-1 TCR T cells are safe and work well to treat acute leukemia that has relapsed after allogeneic BMT